Work

Abstract CT162: Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis

Year: 2021

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2021-ct162

Authors: Abdulraheem Yacoub, Eunice S. Wang, Raajit K. Rampal, Uma Borate, Marina Kremyanskaya, Haris Ali, Gabriela S. Hobbs, Casey O'Connell, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Timothy C. Burn, Naval G. Daver

Institutions: University of Kansas Medical Center, Roswell Park Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, Mount Sinai Hospital, City Of Hope National Medical Center, City of Hope, Massachusetts General Hospital, University of Southern California, Incyte (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3180304259

Cites:

Cited by: 9

Related to: 10